Proteomic Analysis of HLA Complex in Solid Cancers: Breast, Ovary, Colon, Rectum, Stomach, and Pancreas

NCT ID: NCT00419627

Last Updated: 2007-01-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

160 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the presence of proteins in solid tumors which may lead to an immune response

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The main objective of the study is to evaluate which proteins are presented by the HLA complex of solid tumors. Secondary objectives include to evaluate whether an immune response specific to these proteins has actually been provoked and whether there is a similar immune response following recurrence. Real specimens will be evaluated using PCR and mass spectrometry.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Neoplasms Stomach Neoplasms Pancreatic Neoplasms Breast Neoplasms Ovarian Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

NATURAL_HISTORY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with adenocarcinoma of breast, colon, rectum, ovary , stomach, pancreas

Exclusion Criteria

* Withdrawal of consent
* Small specimen which does not allow to retrieve tissue without interfering with pathologic evaluation
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Technion, Israel Institute of Technology

OTHER

Sponsor Role collaborator

Hillel Yaffe Medical Center

OTHER_GOV

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Itamar Ashkenazi, M.D.

Role: PRINCIPAL_INVESTIGATOR

Hillel Yaffe Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hillel Yaffe Medical Center

Hadera, , Israel

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Israel

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Itamar Ashkenazi, M.D.

Role: CONTACT

972-4-6304761

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Itamar Ashkenazi, M.D.

Role: primary

972-4-6304761

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ProtHYMC

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Tissue Microarray of Hematological Malignancies
NCT04142372 ACTIVE_NOT_RECRUITING
The Microbiome in Blood Cancer and HLH
NCT06734624 NOT_YET_RECRUITING